Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: db1f3cdd258212fd708eb11bd772db37b5b16da3
First added on: Feb 07, 2025